Modulation of KCNQ2/3 potassium channels by the novel anticonvulsant retigabine - PubMed (original) (raw)
Modulation of KCNQ2/3 potassium channels by the novel anticonvulsant retigabine
M J Main et al. Mol Pharmacol. 2000 Aug.
Abstract
Retigabine is a novel anticonvulsant with an unknown mechanism of action. It has recently been reported that retigabine modulates a potassium channel current in nerve growth factor-differentiated PC12 cells (), however, to date the molecular correlate of this current has not been identified. In the present study we have examined the effects of retigabine on recombinant human KCNQ2 and KCNQ3 potassium channels, expressed either alone or in combination in Xenopus oocytes. Application of 10 microM retigabine to oocytes expressing the KCNQ2/3 heteromeric channel shifted both the activation threshold and voltage for half-activation by approximately 20 mV in the hyperpolarizing direction, leading to an increase in current amplitude at test potentials between -80 mV and +20 mV. Retigabine also had a marked effect on KCNQ current kinetics, increasing the rate of channel activation but slowing deactivation at a given test potential. Similar effects of retigabine were observed in oocytes expressing KCNQ2 alone, suggesting that KCNQ2 may be the molecular target of retigabine. Membrane potential recordings in oocytes expressing the KCNQ2/3 heteromeric channel showed that application of retigabine leads to a concentration-dependent hyperpolarization of the oocyte, from a resting potential of -63 mV under control conditions to -85 mV in the presence of 100 microM retigabine (IC(50) = 5.2 microM). In control experiments retigabine had no effect on either resting membrane potential or endogenous oocyte membrane currents. In conclusion, we have shown that retigabine acts as a KCNQ potassium channel opener. Because the heteromeric KCNQ2/3 channel has recently been reported to underlie the M-current, it is likely that M-current modulation can explain the anticonvulsant actions of retigabine in animal models of epilepsy.
Similar articles
- Retigabine, a novel anti-convulsant, enhances activation of KCNQ2/Q3 potassium channels.
Wickenden AD, Yu W, Zou A, Jegla T, Wagoner PK. Wickenden AD, et al. Mol Pharmacol. 2000 Sep;58(3):591-600. doi: 10.1124/mol.58.3.591. Mol Pharmacol. 2000. PMID: 10953053 - Activation of expressed KCNQ potassium currents and native neuronal M-type potassium currents by the anti-convulsant drug retigabine.
Tatulian L, Delmas P, Abogadie FC, Brown DA. Tatulian L, et al. J Neurosci. 2001 Aug 1;21(15):5535-45. doi: 10.1523/JNEUROSCI.21-15-05535.2001. J Neurosci. 2001. PMID: 11466425 Free PMC article. - The novel anticonvulsant retigabine activates M-currents in Chinese hamster ovary-cells tranfected with human KCNQ2/3 subunits.
Rundfeldt C, Netzer R. Rundfeldt C, et al. Neurosci Lett. 2000 Mar 17;282(1-2):73-6. doi: 10.1016/s0304-3940(00)00866-1. Neurosci Lett. 2000. PMID: 10713399 - The mechanism of action of retigabine (ezogabine), a first-in-class K+ channel opener for the treatment of epilepsy.
Gunthorpe MJ, Large CH, Sankar R. Gunthorpe MJ, et al. Epilepsia. 2012 Mar;53(3):412-24. doi: 10.1111/j.1528-1167.2011.03365.x. Epub 2012 Jan 5. Epilepsia. 2012. PMID: 22220513 Review. - Potassium channels: how genetic studies of epileptic syndromes open paths to new therapeutic targets and drugs.
Cooper EC. Cooper EC. Epilepsia. 2001;42 Suppl 5:49-54. doi: 10.1046/j.1528-1157.2001.0420s5049.x. Epilepsia. 2001. PMID: 11887968 Review.
Cited by
- The acrylamide (S)-2 as a positive and negative modulator of Kv7 channels expressed in Xenopus laevis oocytes.
Blom SM, Schmitt N, Jensen HS. Blom SM, et al. PLoS One. 2009 Dec 11;4(12):e8251. doi: 10.1371/journal.pone.0008251. PLoS One. 2009. PMID: 20011514 Free PMC article. - Diverse mechanisms of antiepileptic drugs in the development pipeline.
Rogawski MA. Rogawski MA. Epilepsy Res. 2006 Jun;69(3):273-94. doi: 10.1016/j.eplepsyres.2006.02.004. Epub 2006 Apr 18. Epilepsy Res. 2006. PMID: 16621450 Free PMC article. Review. - New molecular targets for antiepileptic drugs: alpha(2)delta, SV2A, and K(v)7/KCNQ/M potassium channels.
Rogawski MA, Bazil CW. Rogawski MA, et al. Curr Neurol Neurosci Rep. 2008 Jul;8(4):345-52. doi: 10.1007/s11910-008-0053-7. Curr Neurol Neurosci Rep. 2008. PMID: 18590620 Free PMC article. Review. - Insights into Cardiac IKs (KCNQ1/KCNE1) Channels Regulation.
Wu X, Larsson HP. Wu X, et al. Int J Mol Sci. 2020 Dec 11;21(24):9440. doi: 10.3390/ijms21249440. Int J Mol Sci. 2020. PMID: 33322401 Free PMC article. Review. - Pharmacological Manipulation of K v 7 Channels as a New Therapeutic Tool for Multiple Brain Disorders.
Vigil FA, Carver CM, Shapiro MS. Vigil FA, et al. Front Physiol. 2020 Jun 19;11:688. doi: 10.3389/fphys.2020.00688. eCollection 2020. Front Physiol. 2020. PMID: 32636759 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases